These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Developments in L2-based human papillomavirus (HPV) vaccines. Schellenbacher C; Roden RBS; Kirnbauer R Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616 [TBL] [Abstract][Full Text] [Related]
5. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses. Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042 [TBL] [Abstract][Full Text] [Related]
7. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426 [TBL] [Abstract][Full Text] [Related]
8. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. Tumban E; Peabody J; Peabody DS; Chackerian B PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066 [TBL] [Abstract][Full Text] [Related]
9. Expression of different L1 isoforms of Fu Y; Cao R; Schäfer M; Stephan S; Braspenning-Wesch I; Schmitt L; Bischoff R; Müller M; Schäfer K; Vinzón SE; Rösl F; Hasche D Elife; 2020 Aug; 9():. PubMed ID: 32746966 [TBL] [Abstract][Full Text] [Related]
11. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer. Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545 [TBL] [Abstract][Full Text] [Related]
12. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer. Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288 [TBL] [Abstract][Full Text] [Related]
13. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing. Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748 [TBL] [Abstract][Full Text] [Related]